Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Medical Research Journal
MENU
Shortcuts Submit an article Author Guidelines Reviewers 2023 Focus and Scope

open access

Vol 3, No 4 (2018)
Original article
Published online: 2018-12-18
View PDF Download PDF file
Get Citation

The possible use of the blood serum concentration measurements of sHLA-G in women with endometrial and cervical cancers during radiotherapy as an indicator of the status of the tumour microenvironment

Konrad Dziobek12, Zbigniew Kojs23, Sebastian Szubert45, Sławomir Wileński45, Maria Szymankiewicz6, Łukasz Wicherek45, Magdalena Dutsch-Wicherek7
DOI: 10.5603/MRJ.a2018.0033
·
Medical Research Journal 2018;3(4):204-210.
Affiliations
  1. Centrum Onkologii w Bydgoszczy, Romanowskiej 2, 85-796 Bydgoszcz
  2. Center of Oncology, M. Sklodowska-Curie Memorial Institute, Cracow Branch, Poland
  3. Center of Oncology, Gynecologic Oncology Department, M. Sklodowska-Curie Memorial Institute, Krakow Branch, Garncarska 11, 31-115 Kraków, Poland
  4. Gynecology and Oncology Department of the Lukaszczyk Oncological Center in Bydgoszcz, Romanowskiej 2, 85-796 Bydgoszcz, Poland
  5. Chair of Radiotherapy, Oncology and Gynecologic Oncology of the Ludwik Rydygier Medical College in Bydgoszcz, Mikolaj Kopernik University, Torun, Poland
  6. Microbiology and Oncological Immunology Department of Ludwik Rydygier Medical College in Bydgoszcz, Mikolaj Kopernik University, Poland
  7. Department of Pediatry Jagiellonian University Medical College

open access

Vol 3, No 4 (2018)
ORIGINAL ARTICLES
Published online: 2018-12-18

Abstract

Background: The selective suppression of cytotoxic immune cells constitutes a crucial event in the development of malignancy. This phenomenon increases in accordance with the growth of a tumor and is just one result of the increased expression in the cancer milieu of those proteins, such as human leukocyte antigen G (HLA-G) and its soluble form (sHLA-G). Given that radiotherapy may influence immune system activity, we aimed to measure (sHLA-G) serum levels both before and after the radiotherapy due to endometrial or cervical cancer.

Methods: We assessed the sHLA-G blood serum concentration levels in a group of 43 patients (28 and 15 diagnosed with cervical cancer and endometrial cacer respectively), who received primary or adjuvant radiotherapy. We assessed the blood serum concentrations of the sHLA-G through a series of measurements taken before and four days after the latest radiation dosage using an ELISA kit.

Results: Median serum sHLA-G levels significantly decreased after radiotherapy (5.63 U/ml; range 0.00 – 344.55; vs 5.57 U/ml; 0.00 –94.02; P = 0.045). The changes of sHLA-G levels didn’t influence patients’ survival. Pretreatment and post-treatment sHLA-G levels were negatively correlated with patients’ age (R Spearman = -0.45, P = 0.041; R Spearman = -0.46. P = 0.038).

Conclusions: The detected levels of sHLA-G blood serum concentrations may supply clinically applicable information regarding the status of the tumor microenvironment — that is, the size and  the degree of  suppression of the tumor environment — where the tumor-immune cell interaction is realized. Finally, this information may also prove helpful in the treatment of cancer.

Abstract

Background: The selective suppression of cytotoxic immune cells constitutes a crucial event in the development of malignancy. This phenomenon increases in accordance with the growth of a tumor and is just one result of the increased expression in the cancer milieu of those proteins, such as human leukocyte antigen G (HLA-G) and its soluble form (sHLA-G). Given that radiotherapy may influence immune system activity, we aimed to measure (sHLA-G) serum levels both before and after the radiotherapy due to endometrial or cervical cancer.

Methods: We assessed the sHLA-G blood serum concentration levels in a group of 43 patients (28 and 15 diagnosed with cervical cancer and endometrial cacer respectively), who received primary or adjuvant radiotherapy. We assessed the blood serum concentrations of the sHLA-G through a series of measurements taken before and four days after the latest radiation dosage using an ELISA kit.

Results: Median serum sHLA-G levels significantly decreased after radiotherapy (5.63 U/ml; range 0.00 – 344.55; vs 5.57 U/ml; 0.00 –94.02; P = 0.045). The changes of sHLA-G levels didn’t influence patients’ survival. Pretreatment and post-treatment sHLA-G levels were negatively correlated with patients’ age (R Spearman = -0.45, P = 0.041; R Spearman = -0.46. P = 0.038).

Conclusions: The detected levels of sHLA-G blood serum concentrations may supply clinically applicable information regarding the status of the tumor microenvironment — that is, the size and  the degree of  suppression of the tumor environment — where the tumor-immune cell interaction is realized. Finally, this information may also prove helpful in the treatment of cancer.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

endometrial cancer, cervical cancer, sHLA-G

About this article
Title

The possible use of the blood serum concentration measurements of sHLA-G in women with endometrial and cervical cancers during radiotherapy as an indicator of the status of the tumour microenvironment

Journal

Medical Research Journal

Issue

Vol 3, No 4 (2018)

Article type

Original article

Pages

204-210

Published online

2018-12-18

Page views

870

Article views/downloads

717

DOI

10.5603/MRJ.a2018.0033

Bibliographic record

Medical Research Journal 2018;3(4):204-210.

Keywords

endometrial cancer
cervical cancer
sHLA-G

Authors

Konrad Dziobek
Zbigniew Kojs
Sebastian Szubert
Sławomir Wileński
Maria Szymankiewicz
Łukasz Wicherek
Magdalena Dutsch-Wicherek

References (30)
  1. Fournel S, Aguerre-Girr M, Huc X, et al. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol. 2000; 164(12): 6100–6104.
    PubMed
  2. Dutsch-Wicherek M, Wicherek L. The association of RCAS1 serum concentration with the reversibility or irreversibility of the process of immune cytotoxic activity restriction during normal menstrual cycle, cancer relapse, and surgical treatment for various types of squamous cell carcinomas and adenocarcinomas. Am J Reprod Immunol. 2008; 59(3): 266–275.
    CrossRefPubMed
  3. Wicherek L. Alterations in RCAS1 serum concentration levels during the normal menstrual cycle and the lack of analogical changes in ovarian endometriosis. Am J Reprod Immunol. 2008; 59(6): 535–544.
    CrossRefPubMed
  4. Rebmann V, Regel J, Stolke D, et al. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol. 2003; 13(5): 371–377.
    PubMed
  5. Wilczynski JR, Kalinka J, Radwan M. The role of T-regulatory cells in pregnancy and cancer. Front Biosci. 2008; 13: 2275–2289.
    PubMed
  6. Sheu BC, Lin RH, Lien HC, et al. Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol. 2001; 167(5): 2972–2978.
    PubMed
  7. Taylor NA, Vick SC, Iglesia MD, et al. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. J Clin Invest. 2017; 127(9): 3472–3483.
    CrossRefPubMed
  8. Muroyama Y, Nirschl TR, Kochel CM, et al. Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment. Cancer Immunol Res. 2017; 5(11): 992–1004.
    CrossRefPubMed
  9. American Cancer Society. Cancer Facts and Figures 2008. Atlanta:American Cancer Society. ; 2008.
  10. Liu S, Sun X, Luo J, et al. Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications. Am J Cancer Res. 2015; 5(11): 3276–3285.
    PubMed
  11. Park GM, Lee S, Park B, et al. Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophys Res Commun. 2004; 313(3): 606–611.
    PubMed
  12. Rebmann V, Regel J, Stolke D, et al. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol. 2003; 13(5): 371–377.
    PubMed
  13. Pistoia V, Morandi F, Wang X, et al. Soluble HLA-G: Are they clinically relevant? Semin Cancer Biol. 2007; 17(6): 469–479.
    CrossRefPubMed
  14. Sheu JJC, Shih IM. Clinical and biological significance of HLA-G expression in ovarian cancer. Semin Cancer Biol. 2007; 17(6): 436–443.
    CrossRefPubMed
  15. Barrier BF, Kendall BS, Sharpe-Timms KL, et al. Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecol Oncol. 2006; 103(1): 25–30.
    CrossRefPubMed
  16. Lefebvre S, Antoine M, Uzan S, et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol. 2002; 196(3): 266–274.
    CrossRefPubMed
  17. El-Chennawi FA, Auf FA, El-Diasty AM, et al. Expression of HLA-G in cancer bladder. Egypt J Immunol. 2005; 12(1): 57–64.
    PubMed
  18. Adithi M, Kandalam M, Ramkumar HL, et al. Retinoblastoma: expression of HLA-G. Ocul Immunol Inflamm. 2006; 14(4): 207–213.
    CrossRefPubMed
  19. Ben Yahia H, Babay W, Bortolotti D, et al. Increased plasmatic soluble HLA-G levels in endometrial cancer. Mol Immunol. 2018; 99: 82–86.
    CrossRefPubMed
  20. Liauw SL, Connell PP, Weichselbaum RR. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med. 2013; 5(173): 173sr2.
    CrossRefPubMed
  21. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012; 366(10): 925–931.
    CrossRefPubMed
  22. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024): 1565–1570.
    CrossRefPubMed
  23. Muroyama Y, Nirschl TR, Kochel CM, et al. Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment. Cancer Immunol Res. 2017; 5(11): 992–1004.
    CrossRefPubMed
  24. Michelin S, Gallegos CE, Dubner D, et al. Ionizing radiation modulates the surface expression of human leukocyte antigen-G in a human melanoma cell line. Hum Immunol. 2009; 70(12): 1010–1015.
    CrossRefPubMed
  25. Chen R, Alvero AB, Silasi DA, et al. Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol. 2007; 57(2): 93–107.
    CrossRefPubMed
  26. Bijen CBM, Bantema-Joppe EJ, de Jong RA, et al. The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int J Cancer. 2010; 126(6): 1417–1427.
    CrossRefPubMed
  27. Emens LA. Chemotherapy and tumor immunity: an unexpected collaboration. Front Biosci. 2008; 13: 249–257.
    PubMed
  28. Li XJ, Zhang X, Lin A, et al. Human leukocyte antigen-G (HLA-G) expression in cervical cancer lesions is associated with disease progression. Hum Immunol. 2012; 73(9): 946–949.
    CrossRefPubMed
  29. Dong Dd, Yang H, Li Ke, et al. Human leukocyte antigen-G (HLA-G) expression in cervical lesions: association with cancer progression, HPV 16/18 infection, and host immune response. Reprod Sci. 2010; 17(8): 718–723.
    CrossRefPubMed
  30. Samuels S, Ferns DM, Meijer D, et al. High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma. Tissue Antigens. 2015; 85(6): 476–483.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl